Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland
During active treatment, MM is primarily treated in the specialized care setting, with outpatient medication and visits to specialized care being the main cost drivers. These results can be utilized to estimate the need for care and expected costs over time due to MM and in health economic evaluations concerning MM.
Authors
- Alvar Kallio (ORCID: https://orcid.org/0009-0001-7269-0421)
- Jarno Ruotsalainen (ORCID: https://orcid.org/0000-0003-1056-3838)
- Timo T. Purmonen (ORCID: https://orcid.org/0000-0001-7794-7495)
- Mikko Kosunen (ORCID: https://orcid.org/0000-0002-0908-5288)
- Maarit Jaana Korhonen (ORCID: https://orcid.org/0000-0002-2953-4757)
- Paavo Raittinen (ORCID: https://orcid.org/0000-0003-4207-8415)
- R. Metsä
- Leena Lehmus (ORCID: https://orcid.org/0009-0004-0494-3900)
Institutions
- Orion Corporation (Finland) (FI)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1007/s41669-024-00524-4
- Citations
- 2
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.26